23:31 , Jul 14, 2017 |  BioCentury  |  Strategy

Transforming BeiGene

BeiGene Ltd. ’s deal with Celgene Corp. for BGB-A317 does more than provide the Chinese biotech with a partner that can compete in the PD-1 space from a development and commercial perspective. It also marks...
20:21 , Jul 7, 2017 |  BC Week In Review  |  Company News

BeiGene grants Celgene PD-1 rights, acquires China operations

BeiGene Ltd. (NASDAQ:BGNE) granted Celgene Corp. (NASDAQ:CELG) exclusive rights in most of the world to its PD-1 inhibitor BGB-A317 for non-hematological indications and acquired Celgene's commercial operations in China, including local rights to a handful...
00:22 , Jul 7, 2017 |  BC Extra  |  Company News

BeiGene grants Celgene PD-1 rights, acquires China operations

BeiGene Ltd. (NASDAQ:BGNE) granted Celgene Corp. (NASDAQ:CELG) exclusive rights in most of the world to its PD-1 inhibitor BGB-A317 for non-hematological indications and acquired Celgene's commercial operations in China, including local rights to a handful...
22:47 , Jan 25, 2017 |  BC Innovations  |  Distillery Therapeutics

Autoimmune disease

INDICATION: Idiopathic thrombocytopenic purpura (ITP); rheumatoid arthritis (RA); autoimmune In vitro and mouse studies suggest an Fc trimer that binds FCGR1 and FCGR2 could help treat ITP, RA and other autoimmune diseases. The trimer consisted...
21:00 , Nov 9, 2016 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Acute myelogenous leukemia (AML) Patient sample, cell culture and mouse studies suggest inhibiting EpCAM could help treat AML. In patient bone marrow cells and peripheral blood mononuclear cells (PBMCs), levels of EpCAM were higher...
08:00 , Feb 16, 2015 |  BC Week In Review  |  Company News

Trillium Diagnostics, Vivione deal

Diagnostic company Vivione will acquire Trillium for $1.5 million in cash and $4 million in stock. Trillium shareholders are eligible for up to $9.5 million in regulatory milestone payments for up to 64 months after...
08:00 , Jan 22, 2015 |  BC Innovations  |  Distillery Techniques

Techniques: Small synthetic antibody-like molecules

Drug platforms TECHNOLOGY: Peptides Chemically synthesized molecules that are about one-twentieth the size of an antibody could possess antibody-like properties and be developed as therapeutics to treat various human diseases, including cancer. The molecules are...
08:00 , Jan 22, 2015 |  BC Innovations  |  Translation in Brief

Boehringer double-dips into academia

Boehringer Ingelheim GmbH announced separate research collaborations last week in immunomodulation and cancer with two U.S. universities. A deal with Yale University focuses on identifying targets for immune modulation in cancer, autoimmune and respiratory indications,...
08:00 , Jan 25, 2010 |  BC Week In Review  |  Company News

LeukoDx, Trillium Diagnostics deal

The companies signed a memorandum of understanding under which LeukoDx will receive exclusive, worldwide rights to Trillium's patent and technology covering the quantification of Fc gamma receptor I ( CD64 ; FCGR1 ) for point...
08:00 , Jan 21, 2010 |  BC Innovations  |  Cover Story

mAbs that live long and prosper

Independent teams at The University of Texas at Austin and Xencor Inc. have come up with strategies to improve the effectiveness and durability of cancer mAbs. Both approaches involve modifying the invariant region common to...